Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Mulls Appeal After Australian Federal Court Rules Crestor Patents Invalid

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca mulls an appeal of an Australian Federal Court judge’s ruling on Crestor patents as the anti-cholesterol drug faces a patent cliff worldwide.

You may also be interested in...



AstraZeneca’s Executive Shakeup Includes Global Strategist To Be Named Later

AstraZeneca's new CEO Pascal Soriot signaled significant change is afoot for the troubled drug maker by eliminating the jobs of R&D President Martin Mackay and Exec VP-Global Commercial Tony Zook.

As Crestor Patent Trial Nears, Generic Firms Seek To Block AstraZeneca Subsidiary From Suit

Defendants in infringement case claim AstraZeneca Pharmaceuticals LP has no rights to the patent at issue.

Cynata Sets Stage For Global Fujifilm Cell Therapy Deal

Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.

Topics

Related Companies

UsernamePublicRestriction

Register

SC083922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel